Co-Authors
This is a "connection" page, showing publications co-authored by Shuai Xia and Qiaoshuai Lan.
Connection Strength
1.508
-
Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduct Target Ther. 2021 07 29; 6(1):288.
Score: 0.240
-
Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. Microbes Infect. 2021 Sep-Oct; 23(8):104840.
Score: 0.237
-
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduct Target Ther. 2020 06 12; 5(1):92.
Score: 0.222
-
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr; 30(4):343-355.
Score: 0.219
-
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 07; 17(7):765-767.
Score: 0.217
-
Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. Viruses. 2019 01 14; 11(1).
Score: 0.201
-
A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharm Sin B. 2021 Aug 02.
Score: 0.060
-
Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human ß-Coronavirus Infection. J Med Chem. 2022 02 24; 65(4):2809-2819.
Score: 0.059
-
Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virol Sin. 2020 06; 35(3):340-343.
Score: 0.055